AbbVie, Inc. (ABBV)

Over the past six months, AbbVie's stock experienced notable events. In February 2026, strong financial results were reported, but the stock dipped following the earnings report. In April 2026, the stock was impacted by the FDA's approval of Johnson & Johnson's Icotyde, raising competition concerns, and broader macro headwinds. AbbVie lowered its Q1 and full-year 2026 earnings outlook due to an R&D charge, negatively impacting near-term earnings expectations. Despite these pressures, some analysts maintained bullish stances, and AbbVie filed a lawsuit to narrow the 340B drug discount program's patient definition.

AbbVie's overall demand seasonality for its products and services does not appear to be highly pronounced. The biopharmaceutical industry tends to have more stable demand driven by ongoing patient needs and new drug approvals. Some analyses suggest that certain months may historically show slightly higher or lower average returns for ABBV stock, with a period of seasonal strength from approximately October 28 to March 19. Quarterly revenue patterns show slight variations, but these are generally minor adjustments.

AbbVie Inc. is an American biopharmaceutical company formed in 2012 as a spin-off from Abbott Laboratories. It focuses on the research, development, manufacturing, and sale of innovative medicines and therapies worldwide, addressing complex health issues across immunology, oncology, neuroscience, and aesthetics. Major products include Humira, Skyrizi, and Rinvoq for immunology; Imbruvica, Venclexta, Elahere and Epkinly for oncology; treatments for neurological disorders; aesthetics products like Botox Cosmetic and the Juvederm Collection; and other key products like Mavyret/Maviret, Norvir, Kaletra, and Zinbryta.

AbbVie has a significant global presence, operating in over 70 countries with offices and research facilities worldwide. Major R&D sites are located in North Chicago, Illinois, Irvine and South San Francisco, California, Cambridge and Worcester, Massachusetts, Ludwigshafen, Germany, and Tokyo, Japan. AbbVie also has a substantial U.S. manufacturing and investment footprint, with a presence in all 50 states and Puerto Rico, and multiple U.S. manufacturing sites.

AbbVie has maintained a strong brand reputation, recognized for its workplace culture and commitment to sustainability. The company has been honored on various 'best workplace' and 'diversity and inclusion' lists. Strategic acquisitions and partnerships, such as the acquisition of Aliada Therapeutics and partnerships with Neomorph and Simcere Zaiming, have bolstered its reputation for innovation and growth. The successful navigation of Humira's patent expiration with the strong performance of newer drugs has also been a key factor.

AbbVie's stock ownership is primarily held by institutional investors, who collectively own approximately 56.64% to 70% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, Geode Capital Management, Llc, Morgan Stanley, Bank Of America Corp /de/, Norges Bank (NBIM), Capital Research Global Investors and Charles Schwab Investment Management Inc.